Wellbeing Digital Sciences Inc KONEF

$MEDI Advances Research Capabilities

[maysilverstone]

With nearly 1 in 5 Americans living with a mental illness or addiction in 2019, the psychedelic sector is expected to grow rapidly as more research and investments go into it.
 

$MEDI is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments.
 

They recently announced
 

- Their wholly-owned contract research organization, KGK Science Inc. has applied for a controlled drugs and substance dealer's license under Canada’s Narcotic Control Regulations.
 

-This will enable KGK to act as a centralized distributor for large, multi-location clinical trials.
 

- Ketamine One completed the pre-qualification audits of its Canadian clinics with KGK for the use of the Company’s facilities in future clinical trials
 

Now KGK will be able to utilize their clinics for trials, expand their patient network, and with approval, have a narcotic dealers license.
 

$MEDI, with 16 clinics across North America, also has first-of-its-kind wearable technologies to track key vitals before, during, and after psychedelic assisted therapies while generating additional revenue. Currently up 10.8% to $1.44 with a mc of $171.38M, this one is on my watchlist in the psychedelic space.
 

https://financialpost.com/globe-newswire/ketamine-one-advances-research-capabilities-via-controlled-substance-dealers-licence-application-the-company-and-its-subsidiary-kgk-science-have-also-completed-the-pre-qualification-audits-of-its-cana